Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic
Effect in New Primate Model of Established Anthrax Infection
Pilot Study Demonstrates 50% Survival in
Valortim-TreatedAnimals PRINCETON, N.J. and ANNAPOLIS, MD., March 29, 2007 - Medarex,Inc. (Nasdaq: MEDX), a leading monoclonal antibody company, andPharmAthene, Inc., a privately held biotechnology company dedicatedto the development of biodefense countermeasures, today announcedthat
Valortim, a fully human monoclonal antibody product candid...
Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic
Effect in New Primate Model of Established Anthrax Infection
Pilot Study Demonstrates 50% Survival in
Valortim-Treated Animals PRINCETON, N.J. and ANNAPOLIS, Md., March 29, 2007/PRNewswire-FirstCall/ -- Medarex, Inc. , a leading monoclonalantibody company, and PharmAthene, Inc., a privately heldbiotechnology company dedicated to the development of biodefensecountermeasures, today announced that
Valortim(TM), a fully humanmonoclon...